Targeting PD-L2-RGMG overcomes microbiome-related immunotherapy resistance.

Publication information:

2023. “Targeting PD-L2-RGMG Overcomes Microbiome-Related Immunotherapy Resistance”. Nature, 617, Pp. 377-85